TABLE 1.
A | |||||||
---|---|---|---|---|---|---|---|
Drug | Ki (nM) | nH | KiH (nM) | % High | KiL (nM) | % Low | n |
Prazosin | 0.33 ± 0.1 | −0.75 ± 0.1 | 4 | ||||
BMY 7378 | 122 ± 27 | −0.87 ± 0.2 | 4 | ||||
5-methylurapidila | −0.58 ± 0.1 | 0.64 ± 0.3 | 21 ± 4 | 91 ± 7 | 79 ± 5 | 5 | |
B | |||||||
% [3H]Prazosin Binding | 19 ± 2 | 71 ± 3 | |||||
Sucrose Density Gradient Fraction Number | 3 – 5b | 9 – 10c |
A. The values are mean ± S.E.M.; n, number of separate SMG-C10 cell cultures. Ki, is affinity in nM of drugs for inhibiting specific [125I]HEAT binding; nH, Hill coefficient. Affinity values from binding data that fit best to a two-site binding model are expressed as KiH (high-affinity binding site) and KiL (low-affinity binding site). % High, percentage of high-affinity binding sites; % Low, percentage of low affinity binding sites. B. % [3H]Prazosin Binding, percentage of specific [3H]prazosin binding sites in subcellular fractions separated by sucrose density gradient centrifugation. Values are mean ± S.E.M. of five experiments using separate SMG-C10 cell cultures.
Competition binding curves fit best by nonlinear least-squares curve-fitting regression to a two-site binding model (p < 0.05) using the F test.
Fractions containing intracellular vesicles.
Fractions containing plasma membranes.